RENAL-SPECIFIC INFLAMMATORY AND CYTOTOXIC EFFECTS OF PUBERULIC ACID

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 


 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/07f33a1f9540007afaa8d051597cc71f.pdf
RENAL-SPECIFIC INFLAMMATORY AND CYTOTOXIC EFFECTS OF PUBERULIC ACID

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Takuo
Hirose
Takuo Hirose hirose.takuo@tohoku-mpu.ac.jp Tohoku Medical and Pharmaceutical University Division of Nephrology and Hypertension Sendai Japan * Tohoku Medical and Pharmaceutical University Division of Integrative Renal Replacement Therapy Sendai Japan
Jun Takai j-takai@tohoku-mpu.ac.jp Tohoku Medical and Pharmaceutical University Division of Medical Biochemistry Sendai Japan -
Ayaka Kamada ayaka.kamada@tohoku-mpu.ac.jp Tohoku Medical and Pharmaceutical University Division of Nephrology and Hypertension Sendai Japan -
Shigemitsu Sato sshige@tohoku-mpu.ac.jp Tohoku Medical and Pharmaceutical University Division of Integrative Renal Replacement Therapy Sendai Japan -
Chika Takahashi c.takahashi@tohoku-mpu.ac.jp Tohoku Medical and Pharmaceutical University Division of Integrative Renal Replacement Therapy Sendai Japan -
Hiroki Ito hito@tohoku-mpu.ac.jp Tohoku Medical and Pharmaceutical University Division of Nephrology and Hypertension Sendai Japan -
Risa Ishikawa sr4111@hosp.tohoku-mpu.ac.jp Tohoku Medical and Pharmaceutical University Division of Nephrology and Hypertension Sendai Japan -
Akari Endo endoakari820@tohoku-mpu.ac.jp Tohoku Medical and Pharmaceutical University Division of Nephrology and Hypertension Sendai Japan -
Ikuko Oba-Yabana iku-yabana@tohoku-mpu.ac.jp Tohoku Medical and Pharmaceutical University Division of Nephrology and Hypertension Sendai Japan -
Takefumi Mori tmori@tohoku-mpu.ac.jp Tohoku Medical and Pharmaceutical University Division of Nephrology and Hypertension Sendai Japan - Tohoku Medical and Pharmaceutical University Division of Integrative Renal Replacement Therapy Sendai Japan
-
-
-
-
-

Between late 2023 and early 2024, numerous cases of severe kidney dysfunction were reported in Japan among individuals who had taken beni-koji (red yeast rice) supplements contaminated with puberulic acid. Puberulic acid is a metabolite produced by certain Penicillium species. The information regarding the affected renal structures and underlying mechanisms remains limited. This study aimed to elucidate the localization of puberulic acid–induced inflammation in vivo and to assess its direct cytotoxic effects on cultured renal tubular cells.

Interleukin-6 (IL6) reporter mice (IL6-Luc) were intraperitoneally administered puberulic acid (5 mg/kg) or lipopolysaccharide (LPS) to visualize in vivo inflammatory responses using a bioluminescence imaging system. To evaluate tissue injury, C57BL/6 mice received intraperitoneal injections of puberulic acid (5 mg/kg), and kidney tissues were analyzed 2 days post-injection. Human proximal tubular epithelial cells (HK-2) were exposed to puberulic acid in vitro. Cell viability was assessed using the WST-8 assay, and protein expression was analyzed by Western blotting.

Results: In IL6-Luc mice, LPS induced a systemic inflammatory response throughout the body, whereas puberulic acid elicited a localized bioluminescent signal predominantly in the kidney region. In C57BL/6 mice, the administration of puberulic acid resulted in the expansion of the interstitial areas that were positive for transforming growth factor-β1 (TGFB1) and the macrophage markers CD68 and CD206. In vitro, HK-2 cells exposed to puberulic acid showed a concentration-dependent decline in viable cell numbers. The upregulation of mitochondrial injury markers was observed in Western blot analysis.

Puberulic acid specifically induces renal inflammation and exerts cytotoxic effects on proximal tubular epithelial cells through mitochondrial injury. These findings suggest that the kidney is a primary target organ for puberulic acid toxicity and that mitochondrial impairment may be a key mechanism underlying puberulic acid–induced nephropathy. Further studies are warranted to elucidate the molecular pathways involved and to evaluate the clinical relevance of puberulic acid exposure in humans.

Kewords